Richard L Lindstrom Md bought $461k of OCUL
director at OCULAR THERAPEUTIX, INC. 60,229 shares at an average of $7.66, traded Feb 20, 2026, filed Feb 24, 2026.
Score components
- +15RoleDirector
- +17Trade size$461k at market
- +6Relative to holdingsHoldings up 32%
- +8Price context52% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.9%, 3m -7.4%, 6m +21.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-019256, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | POpen-market purchase Common Stock | +60,229 | $7.66 | $461k | 246,933 | Feb 24, 2026 |
Related signals
Other insiders at OCULAR THERAPEUTIX, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 20, 2026 | OCULAR THERAPEUTIX, INC | Todd Anderman Chief Legal Officer | $87k 11,984 shares | -8% | |
| 18Weak | OCULAR THERAPEUTIX, INC | Jeffrey S. Heier Chief Scientific Officer | $77k 10,869 shares | -3% | |
| 18Weak | OCULAR THERAPEUTIX, INC | Peter Kaiser Chief Development Officer | $70k 9,990 shares | -4% | |
| 35Weak | OCULAR THERAPEUTIX, INC | Donald Notman Chief Operating Officer | $11k 1,099 shares | -0% | |
| 23Weak | OCULAR THERAPEUTIX, INC | Pravin Dugel See Remarks | $233k 21,649 shares | -1% | |
| 16Weak | OCULAR THERAPEUTIX, INC | Jeffrey S. Heier Chief Scientific Officer | $36k 3,296 shares | -1% | |
| 16Weak | OCULAR THERAPEUTIX, INC | Peter Kaiser Chief Development Officer | $33k 3,035 shares | -1% | |
| 10Weak | OCULAR THERAPEUTIX, INC | Sanjay Nayak Chief Strategy Officer | $20k 1,897 shares | -1% | |
| 20Weak | OCULAR THERAPEUTIX, INC | Nadia Waheed Chief Medical Officer | $123k 14,828 shares | -5% | |
| 21Weak | OCULAR THERAPEUTIX, INC | Pravin Dugel See Remarks | $173k 21,156 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.